Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 6 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 6 of 10.)

DateHeadlineEventSource5-minTo close
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)Press releasePR Newswire-0.04%+0.32%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.08%+0.28%
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four YearsPress releaseBusiness Wire+0.12%+0.39%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025Press releasePR Newswire-0.10%+0.01%
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's diseasePress releasePR Newswire+0.12%+0.39%
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designationPress releasePR Newswire+0.02%+0.50%
Form ARS JOHNSON & JOHNSON For: Dec 29SEC filing · Form ARSSEC EDGAR-0.34%-0.54%
Form DEF 14A JOHNSON & JOHNSON For: Mar 12SEC filing · Form DEFSEC EDGAR-0.34%-0.54%
Form DEFA14A JOHNSON & JOHNSONSEC filing · Form DEFA14ASEC EDGAR-0.34%-0.54%
Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerPress releaseCanada Newswire+1.25%+0.13%
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patientsPress releasePR Newswire+1.25%+0.13%
Six Dean Omar Branham Shirley Partners Honored for Representation of PlaintiffsPress releaseBusiness Wire-0.19%-0.80%
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasisPress releasePR Newswire+1.25%+0.13%
Johnson & Johnson to Host Investor Conference Call on First-Quarter ResultsPress releaseBusiness Wire+0.22%+0.42%
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor RelationsPress releaseBusiness Wire+0.73%+0.37%
Form CERT JOHNSON & JOHNSONSEC filing · Form CERTSEC EDGAR+0.09%+0.99%
Form 8-A12B JOHNSON & JOHNSONSEC filing · Form 8-A12BSEC EDGAR+0.05%+0.88%
Form 8-K JOHNSON & JOHNSON For: Feb 26SEC filing · Form 8-KSEC EDGAR+0.05%+0.88%
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitisPress releasePR Newswire-0.07%+1.51%
Form 8-K JOHNSON & JOHNSON For: Feb 20SEC filing · Form 8-KSEC EDGAR-0.07%+1.51%
E.C. Schultek announces the release of his debut book, 'The Ten: Short Stories of Ten Business Leaders Who Left a Legacy'Press releasePR Web+0.11%+1.67%
Form 10-K JOHNSON & JOHNSON For: Dec 29SEC filing · Form 10-KSEC EDGAR-0.27%-0.72%
Form 13F-HR JOHNSON & JOHNSON For: Dec 31SEC filing · Form 13F-HRSEC EDGAR+0.00%-0.32%
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseasesPress releasePR Newswire-0.17%+1.28%
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare ConferencePress releaseBusiness Wire+0.31%+1.43%
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the InvestigationPress releaseAccesswire+0.07%+0.03%
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet NeurologyPress releasePR Newswire+0.20%+1.04%
Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colourPress releaseCanada Newswire+0.20%+1.04%
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities InvestigationPress releaseAccesswire+0.54%+1.89%
Form 8-K JOHNSON & JOHNSON For: Jan 22SEC filing · Form 8-KSEC EDGAR-0.38%+0.88%
Form 8-K/A JOHNSON & JOHNSON For: Jan 22SEC filing · Form 8-KSEC EDGAR+0.20%+1.04%
Johnson & Johnson Reports Q4 and Full-Year 2024 ResultsPress releaseBusiness Wire-0.38%+0.88%
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to ConnectPress releaseAccesswire+0.06%-0.17%
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depressionPress releasePR Newswire+0.48%+0.54%
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Stockholders to Inquire about Securities InvestigationPress releaseAccesswire+0.48%+0.54%
Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationPress releaseAccesswire-0.12%-0.43%
RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancerPress releaseCanada Newswire+0.42%+2.39%
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Stockholders to ConnectPress releaseAccesswire-0.12%-0.43%
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancerPress releasePR Newswire+0.32%-0.23%
Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationPress releaseAccesswire-0.15%+0.81%
Tickets and Sponsorships Available for the 2025 Prevent Blindness Person of Vision Award Gala, to be Held During Vision Expo East, Honoring Howard Purcell, O.D., NECOPress releasePR Web-0.02%+1.12%
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Stockholders to Learn More About the InvestigationPress releaseAccesswire-0.24%+0.89%
Dean Omar Branham Shirley’s Partners Named to List of 500 Leading Lawyers in AmericaPress releaseBusiness Wire+0.04%+0.42%
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.Press releaseBusiness Wire+0.46%+1.04%
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Investors to Inquire about Securities InvestigationPress releaseAccesswire+0.46%+1.04%
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravisPress releasePR Newswire+0.96%+0.98%
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's DiseasePress releasePR Newswire-2.24%-2.21%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinibPress releasePR Newswire+0.49%+1.78%
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025Press releaseBusiness Wire+0.01%-0.83%
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare ConferencePress releaseBusiness Wire+0.25%+0.66%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground